AbbVie’s New, Cheaper Hepatitis C Drug Could Launch The Drug World’s Own Hunger Games
AbbVie Inc.’s newly approved drug Mavyret can treat hepatitis C’s six major strains in eight weeks.
It’s also a positive steal in the hepatitis C drug world, at $26,400 for a eight-week course of treatment.
That’s on paper, at least, according to a chart from EvercoreISI analyst Umer Raffat, which shows AbbVie’s Mavyret coming in cheaper than the company’s other hepatitis C therapies, Viekira Pak and Viekira XR, Gilead Sciences Inc.’s Sovaldi, Harvoni, Epclusa and Vosevi, and Merck’s Zepatier.
It’s also a positive steal in the hepatitis C drug world, at $26,400 for a eight-week course of treatment.
That’s on paper, at least, according to a chart from EvercoreISI analyst Umer Raffat, which shows AbbVie’s Mavyret coming in cheaper than the company’s other hepatitis C therapies, Viekira Pak and Viekira XR, Gilead Sciences Inc.’s Sovaldi, Harvoni, Epclusa and Vosevi, and Merck’s Zepatier.